New York-based Maypro Industries has been named the US distributor of AmealPeptide, a patented clinically proven ingredient for healthy blood pressure from Calpis, Co., Ltd.
The ingredient has previously been available in the US and is currently being used in various supplement brands, a spokesperson for Maypro told NutraIngredients-USA, and Maypro will be selling to existing customers as well as new customers for this ingredient.
The ingredient is derived from enzymatically hydrolyzed casein and it acts as an ACE inhibitor. ACE inhibitors work by inhibiting the conversion of angiotensin I to the potent vasoconstrictor, angiotensin II, thereby improving blood flow and blood pressure. The ingredient’s efficacy is backed by 14 double-blind, placebo-controlled studies, said the company.
The spokesperson said that the structure-function claim used for the ingredient is: ‘Helps to maintain a healthy blood pressure level that is already within the normal range’.
“Through Maypro’s distribution network, we hope more people will get a chance to take AmealPeptide so that we contribute to the improvement of everyone’s quality of life” said Shunsuke Fuji, senior officer, Calpis.
“It is an honor for us to represent one of Japan’s leading beverage companies and to offer a product supported by such an extensive body of clinical research,” said Steve Yamada, Maypro’s CEO.